

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and a Waiver under 18 U.S.C. §208(b)(3)

**Cassandra Henderson, M.D.**

**Committee:** Reproductive Health Drugs Advisory Committee

**Meeting Date:** August 29, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to supplemental new drug application (NDA) 21-945, 17 alpha-hydroxyprogesterone caproate 250 mg/mL injection, sponsored by Adeza Biomedical Corporation for the proposed indication of the prevention of preterm delivery in women with a history of a prior preterm delivery, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Member of a Speaker's Bureau	Sponsor	Less than \$10,001

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

\_\_\_\_\_/s/\_\_\_\_\_  
Signature of SGE

\_\_\_\_\_/7/6/06\_\_\_\_\_  
Date